Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis.

Trissal MC, Wong TN, Yao JC, Ramaswamy R, Kuo I, Baty J, Sun Y, Jih G, Parikh N, Berrien-Elliott MM, Fehniger TA, Ley TJ, Maillard I, Reddy PR, Link DC.

Cancer Res. 2018 Jul 1;78(13):3510-3521. doi: 10.1158/0008-5472.CAN-17-3592. Epub 2018 May 3.

PMID:
29724719
2.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS.

Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20.

PMID:
29463563
3.

CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.

Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA.

J Clin Invest. 2017 Nov 1;127(11):4042-4058. doi: 10.1172/JCI90387. Epub 2017 Oct 3.

4.

Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.

Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, Fehniger TA.

Blood. 2017 Jan 26;129(4):473-483. doi: 10.1182/blood-2016-07-729954. Epub 2016 Nov 14.

5.

Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and FcγRIIIa-Triggered Responses.

Wagner JA, Berrien-Elliott MM, Rosario M, Leong JW, Jewell BA, Schappe T, Abdel-Latif S, Fehniger TA.

Biol Blood Marrow Transplant. 2017 Mar;23(3):398-404. doi: 10.1016/j.bbmt.2016.11.018. Epub 2016 Nov 25.

6.

Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes.

Klevorn LE, Berrien-Elliott MM, Yuan J, Kuehm LM, Felock GD, Crowe SA, Teague RM.

Cancer Immunol Res. 2016 Dec;4(12):1016-1026. Epub 2016 Nov 1.

7.

Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Cantoni C, Cignarella F, Ghezzi L, Mikesell B, Bollman B, Berrien-Elliott MM, Ireland AR, Fehniger TA, Wu GF, Piccio L.

Acta Neuropathol. 2017 Jan;133(1):61-77. doi: 10.1007/s00401-016-1621-6. Epub 2016 Oct 4.

8.

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, Claas F, Cooper MA, Fehniger TA.

Sci Transl Med. 2016 Sep 21;8(357):357ra123. doi: 10.1126/scitranslmed.aaf2341.

9.

Improving natural killer cell cancer immunotherapy.

Berrien-Elliott MM, Romee R, Fehniger TA.

Curr Opin Organ Transplant. 2015 Dec;20(6):671-80. doi: 10.1097/MOT.0000000000000243. Review.

10.

MicroRNA-15/16 Antagonizes Myb To Control NK Cell Maturation.

Sullivan RP, Leong JW, Schneider SE, Ireland AR, Berrien-Elliott MM, Singh A, Schappe T, Jewell BA, Sexl V, Fehniger TA.

J Immunol. 2015 Sep 15;195(6):2806-17. doi: 10.4049/jimmunol.1500949. Epub 2015 Aug 12.

11.

Human Cytokine-Induced Memory-Like Natural Killer Cells.

Berrien-Elliott MM, Wagner JA, Fehniger TA.

J Innate Immun. 2015;7(6):563-71. doi: 10.1159/000382019. Epub 2015 Apr 30. Review.

12.

Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.

Berrien-Elliott MM, Yuan J, Swier LE, Jackson SR, Chen CL, Donlin MJ, Teague RM.

Cancer Immunol Res. 2015 Feb;3(2):116-24. doi: 10.1158/2326-6066.CIR-14-0159. Epub 2014 Dec 16.

13.

Inflammation programs self-reactive CD8+ T cells to acquire T-box-mediated effector function but does not prevent deletional tolerance.

Jackson SR, Yuan J, Berrien-Elliott MM, Chen CL, Meyer JM, Donlin MJ, Teague RM.

J Leukoc Biol. 2014 Sep;96(3):397-410. doi: 10.1189/jlb.1A0913-500RR. Epub 2014 May 13.

14.

CD8+ T cell exhaustion during persistent viral infection is regulated independently of the virus-specific T cell receptor.

Jackson SR, Berrien-Elliott MM, Meyer JM, Wherry EJ, Teague RM.

Immunol Invest. 2013;42(3):204-20. doi: 10.3109/08820139.2012.751397. Epub 2013 Mar 5.

15.

Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.

Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, Yagita H, Greenberg PD, DiPaolo RJ, Teague RM.

Cancer Res. 2013 Jan 15;73(2):605-16. doi: 10.1158/0008-5472.CAN-12-2179. Epub 2012 Nov 27.

Supplemental Content

Loading ...
Support Center